In this episode of The Oncology Insights Podcast, Dr. Thomas Marron, Director of the Early Phase Trials Unit at Mount Sinai, explains how immunotherapy has reshaped cancer treatment. He discusses checkpoint inhibitors, cancer vaccines, cellular therapies, and the challenges of early-onset cancers. Learn how inflammation and aging impact immune response and what innovations are on the horizon. Listen now on all major platforms!

"Tumors often contain more immune cells than cancer cells, highlighting how critical immune dysfunction is in cancer development."

Meet the guest: Dr. Thomas Marron is Director of the Early Phase Trials Unit at Mount Sinai and a Professor of Medicine, Hematology, and Immunotherapy. With both an MD and PhD in Immunology, his research focuses on novel cancer immunotherapies and personalized vaccine strategies. He leads clinical trials that explore immune mechanisms and tumor biology in solid tumors.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (00:43) Introduction
• (01:57) Checkpoint inhibitor evolution
• (12:41) Cancer vaccine development
• (16:25) CAR-T therapy limits
• (20:01) Role of inflammation
• (25:38) Early-onset cancer trends
• (29:43) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

I’m Dr. Steven Rosen, and I am pleased to introduce the first episode of The Oncology Insights Podcast. This podcast is created for professionals dedicated to advancing cancer care. In the episodes ahead, I’ll be joined by Dr. Abbie Begnaud, Associate Professor of Pulmonary and Critical Care at the University of Minnesota, and Dr. William Oh, Director of Precision Medicine at Yale Cancer Center and Smilow. Together, we will examine the latest research and essential topics that are shaping the future of oncology.

In this episode of The Oncology Insights Podcast, Dr. Joseph Mikhael, Professor at TGen and Chief Medical Officer of the International Myeloma Foundation, explores the evolving landscape of multiple myeloma care. He discusses optimal drug regimens, immunotherapies, health disparities, and the promise of MRD testing and early intervention. Understand how cutting-edge strategies are extending and improving patient lives. Listen now on all major platforms!

“The vast majority of patients treated with multiple myeloma today as their initial therapy should receive a quadruple.”

Meet the guest: Dr. Joseph Mikhael is Professor at the Translational Genomics Research Institute and Chief Medical Officer of the International Myeloma Foundation. With extensive expertise in plasma cell disorders, his work focuses on advancing clinical research, patient education, and addressing disparities in multiple myeloma care.

What you will learn:

• (00:00) Highlight
• (00:38) Introduction
• (12:38) Quadruplet therapy today
• (21:39) Car-T outcomes
• (24:42) Bispecifics in treatment
• (33:38) Bone health support
• (34:38) Early intervention debate
• (38:50) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

On July 21st, we officially launch The Oncology Insights Podcast, your new go-to source for cutting-edge conversations in cancer care. Every episode brings clinical depth, scientific rigor, and global perspective to the innovations reshaping oncology today.

With expert hosts Dr. Abbie Begnaud, Dr. Steven Rosen, and Dr. William Oh, you'll gain access to high-impact discussions designed for those at the forefront of oncology.

Be the first to listen.

Subscribe now to get email alerts for each new episode and exclusive insights straight to your inbox.

www.oncologyinsightspodcast.com

The future of oncology starts here.